Alzheimer's Disease (AD) is a challenging neurodegenerative condition, with overwhelming
implications for affected individuals and healthcare systems worldwide. Animal models have …

There is a molecular coupling between neurodegenerative diseases, including
glaucomatous neurodegeneration (GN), Alzheimer's disease (AD), and Parkinson's disease …

The neurotoxicant trimethyltin (TMT) triggers cognitive impairment and hippocampal
neurodegeneration. TMT is a useful research tool for the study of Alzheimer's disease (AD) …

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by
abnormal accumulation of tau proteins and amyloid-β, leading to neuronal death and …

Microvascular brain endothelial cells tightly limit the entry of blood components and
peripheral cells into the brain by forming the blood–brain barrier (BBB). The BBB is …

Alzheimer's disease (AD) is a progressive, degenerative disorder of the central nervous
system. Despite extensive research conducted on this disorder, its precise pathogenesis …

Two dual fluorescent/phosphorescent tris-heteroleptic mononuclear Ru (ΙΙ) complexes (2
and 3) were designed and applied in amyloid-β (Aβ) sensing. These complexes have a …

Background The approval of new disease-modifying therapies by the US Food and Drug
Administration and the European Medicine Agency makes it necessary to optimize non …

Several decades of research on cell and animal models contributed tremendously to
understanding human diseases. Particularly, research on rodents and non-human primates …

Amyloid-β peptide (Aβ) is a critical cause of Alzheimer's disease (AD). It is generated from
amyloid precursor protein (APP) through cleavages by β-secretase and γ-secretase. γ …